Results 91 to 100 of about 6,539 (200)

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study [PDF]

Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce.
Bagnasco D., Beghe B., Blasi F., Bondi B., Braido F., Cameli P., Caminati M., Canonica G. W., Caruso C., Crimi C., El Masri Y., Giordani J., Guarnieri G., Latorre M., Mastrototaro A., Maule M., Menzella F., Micheletto C., Paggiaro P., Pini A., Pini L., Piras S., Senna G., Spanevello A., Vianello A., Visca D., Zappa M.   +26 more
core   +2 more sources

Targeting eosinophils: severe asthma and beyond [PDF]

, 2019
Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma ...
Caminati, Marco, Guidolin, Lucia, Menzella, Francesco, Senna, Gianenrico   +3 more
core   +1 more source

Effect of benralizumab treatment on the airway microbiome in COPD

ERJ Open Research
Background One-third of patients with COPD have an eosinophilic inflammatory phenotype. Benralizumab is an afucosylated humanised monoclonal antibody that targets the interleukin-5 receptor α subunit, leading to rapid and near-complete eosinophil ...
Koirobi Haldar, Vijay Mistry, Mathew Richardson, Corinne Hamblet, Maria Jison, Michael R. Barer, Christopher McCrae, Christopher E. Brightling   +7 more
doaj   +1 more source

Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use

Therapeutics and Clinical Risk Management, 2018
Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai &ndash ...
Maselli DJ, Rogers L, Peters JI
doaj  

Benralizumab in Real Life [PDF]

Journal of Investigational Allergology and Clinical Immunology, 2021
J C, Miralles López, A I, Escudero Pastor, A, Carbonell Martínez, C, Navarro Garrido, Y, Bonilla Pacheco, Y, Petrik Petrik   +5 more
openaire   +2 more sources

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

Journal of Asthma and Allergy, 2019
J Mark FitzGerald,1 Eugene R Bleecker,2 Arnaud Bourdin,3 William W Busse,4 Gary T Ferguson,5 Laura Brooks,6 Peter Barker,6 Ubaldo J Martin6 1Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung ...
FitzGerald JM, Bleecker ER, Bourdin A, Busse WW, Ferguson GT, Brooks L, Barker P, Martin UJ   +7 more
doaj  

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab

International Journal of COPD, 2019
Leena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of ...
George L, Wright A, Mistry V, Sutcliffe A, Chachi L, Haldar K, Ramsheh MY, Richardson M, van der Merwe R, Martin U, Newbold P, Brightling CE   +11 more
doaj  

Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial

Allergology International
Background: Biologics are integral in the management of severe asthma. As the effectiveness of the anti-IL-5 receptor antibody benralizumab in Japan remains elusive, this study aimed to assess its real-world effectiveness in Japanese patients with severe
Katsunori Masaki, Maho Suzukawa, Hitoshi Sasano, Norihiro Harada, Yasunari Miyazaki, Hideki Katsura, Etsuko Tagaya, Junko Terada, Masayuki Hojo, Naoya Sugimoto, Hiroyuki Nagase, Yuta Kono, Hisato Hiranuma, Yasuhiro Gon, Ryo Takemura, Misato Irie, Reina Nakamura, Hiroki Kabata, Jun Miyata, Koichi Fukunaga   +19 more
doaj   +1 more source

Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab

ACR Open Rheumatology
Objective In the phase 3 head‐to‐head MANDARA study (NCT04157348), benralizumab demonstrated noninferiority to mepolizumab in inducing remission (defined as Birmingham Vasculitis Activity Score [BVAS] of 0 and oral glucocorticoid [OGC] dosage ≤4 mg/day ...
Michael E. Wechsler, Nancy Agmon‐Levin, David R. W. Jayne, Christian Pagnoux, Ulrich Specks, Lena Börjesson Sjö, Sofia Necander, Anat Shavit, Claire Walton, Peter A. Merkel   +9 more
doaj   +1 more source

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study

Frontiers in Allergy
IntroductionSevere eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients ...
Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Giorgio Walter Canonica, Cristiano Caruso, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Laura Malerba, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Maria D’Amato   +24 more
doaj   +1 more source